Discontinuation of medication due to adverse events · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors may leads to lower discontinuation due to adverse events Range of compared with any second‐line chemotherapy (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors showed no clear difference in discontinuation due to adverse events Range of compared with any first‐line chemotherapy (low certainty).
1 finding from 1 review
Intervention not reported
Time to initiation of first subsequent therapy This outcome was not reported as a time‐to‐event outcome. Instead, authors of the trials reported the number of participants who received subsequent anticancer therapy after discontinuation of trial t... · people with a confirmed diagnosis of advanced renal cell carcinoma (combined risk groups) without previous systemic anticancer therapy
The intervention may leads to lower time to initiation of first subsequent therapy This outcome was not… (low certainty).
1 finding from 1 review
Intervention not reported
Discontinuation of study drug due to adverse events · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The intervention probably leads to lower discontinuation of study drug due to adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Discontinuation of study drug due to adverse events · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
B4: Discontinuation of therapy due to maternal adverse effects – an all women · the woman
1 finding from 1 review
Persistence of visual improvement one month after discontinuation of treatment · participants with acute or chronic CME following cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Persistence of visual improvement one month after discontinuation of treatment · participants with acute CME (< 4 months) following cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Persistence of visual improvement one month after discontinuation of treatment · participants with chronic CME (≥ 4 months) following cataract surgery
It is very uncertain whether NSAID changes persistence of visual improvement one month after discontinuation of… compared with placebo (very low certainty).
1 finding from 1 review
Clinically significant adverse events leading to discontinuation · people with asthma
Mepolizumab intravenous (IV) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).
1 finding from 1 review
Clinically significant adverse events leading to discontinuation · people with asthma
Reslizumab intravenous (IV) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).
1 finding from 1 review
Clinically significant adverse events leading to discontinuation · people with asthma
Reslizumab subcutaneous (SC) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (moderate certainty).
1 finding from 1 review
Clinically significant adverse events leading to discontinuation · people with asthma
Benralizumab subcutaneous (SC) leads to higher clinically significant adverse events leading to discontinuation compared with placebo (high certainty).
1 finding from 1 review
Clinically significant adverse events leading to discontinuation · people with asthma
Mepolizumab subcutaneous (SC) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with treatment‐emergent adverse events (TEAEs) ‐ Leading to discontinuation during the treatment period № of participants: 36 (1 RCT) · people with newly diagnosed epilepsy
It is very uncertain whether clonazepam changes proportion of participants with treatment‐emergent adverse events… compared with carbamazepine (very low certainty).
1 finding from 1 review
RR 2.61 [0.8, 8.52]
Studies not reported
Very low
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found